482 related articles for article (PubMed ID: 17652653)
1. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Daum RS
N Engl J Med; 2007 Jul; 357(4):380-90. PubMed ID: 17652653
[No Abstract] [Full Text] [Related]
2. Caution when reconsidering empiric antimicrobial therapy for methicillin-resistant Staphylococcus aureus skin and soft-tissue infections.
da Silva LV; Zavascki AP; de Souza MV; Marcadenti A
Am J Surg; 2008 Oct; 196(4):618-9. PubMed ID: 18809069
[No Abstract] [Full Text] [Related]
3. Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Creech CB; Beekmann SE; Chen Y; Polgreen PM
Pediatr Infect Dis J; 2008 Mar; 27(3):270-2. PubMed ID: 18277924
[TBL] [Abstract][Full Text] [Related]
4. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
Widmer AF
Clin Infect Dis; 2008 Mar; 46(5):656-8. PubMed ID: 18225983
[No Abstract] [Full Text] [Related]
5. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Whitman TJ
Dis Mon; 2008 Dec; 54(12):780-6. PubMed ID: 18996280
[No Abstract] [Full Text] [Related]
6. Emerging drugs for complicated skin and skin-structure infections.
Mendoza N; Tyring SK
Expert Opin Emerg Drugs; 2010 Sep; 15(3):509-20. PubMed ID: 20557269
[TBL] [Abstract][Full Text] [Related]
7. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus.
Lee MC; Rios AM; Aten MF; Mejias A; Cavuoti D; McCracken GH; Hardy RD
Pediatr Infect Dis J; 2004 Feb; 23(2):123-7. PubMed ID: 14872177
[TBL] [Abstract][Full Text] [Related]
8. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus.
Elliott DJ; Zaoutis TE; Troxel AB; Loh A; Keren R
Pediatrics; 2009 Jun; 123(6):e959-66. PubMed ID: 19470525
[TBL] [Abstract][Full Text] [Related]
9. Treatment and prevention of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Popovich KJ; Hota B
Dermatol Ther; 2008; 21(3):167-79. PubMed ID: 18564247
[TBL] [Abstract][Full Text] [Related]
10. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus.
Pallin DJ; Egan DJ; Pelletier AJ; Espinola JA; Hooper DC; Camargo CA
Ann Emerg Med; 2008 Mar; 51(3):291-8. PubMed ID: 18222564
[TBL] [Abstract][Full Text] [Related]
11. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
Stryjewski ME; Chambers HF
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S368-77. PubMed ID: 18462092
[TBL] [Abstract][Full Text] [Related]
12. Serious staphylococcal infections--cyclic lipopeptides: meeting new challenges.
Graninger W
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():1-2. PubMed ID: 18226083
[No Abstract] [Full Text] [Related]
13. Community associated methicillin resistant staphylococcal infections in a pediatric urology practice.
Koski ME; DeMarco RT; Brock JW; Pope JC; Adams MC; Thomas JC
J Urol; 2008 Mar; 179(3):1098-101. PubMed ID: 18206937
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic options for treating community-acquired MRSA.
Powell JP; Wenzel RP
Expert Rev Anti Infect Ther; 2008 Jun; 6(3):299-307. PubMed ID: 18588495
[TBL] [Abstract][Full Text] [Related]
15. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections.
Fergie J; Purcell K
Pediatr Infect Dis J; 2008 Jan; 27(1):67-8. PubMed ID: 18162942
[No Abstract] [Full Text] [Related]
16. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children.
Marcinak JF; Frank AL
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):91-100. PubMed ID: 16441212
[TBL] [Abstract][Full Text] [Related]
17. Drugs for MRSA skin and soft-tissue infections.
Med Lett Drugs Ther; 2014 May; 56(1442):39-40. PubMed ID: 24818839
[No Abstract] [Full Text] [Related]
18. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.
Ruhe JJ; Smith N; Bradsher RW; Menon A
Clin Infect Dis; 2007 Mar; 44(6):777-84. PubMed ID: 17304447
[TBL] [Abstract][Full Text] [Related]
19. Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections.
Odell CA
Curr Opin Pediatr; 2010 Jun; 22(3):273-7. PubMed ID: 20386450
[TBL] [Abstract][Full Text] [Related]
20. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
